|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Germline SNVs were matched against somatic tumor SNVs (i.e., tumor mutations) over twenty TCGA datasets to identify 23 germline-somatic matched, deleterious AA substitutions in coding regions for FLG, TTN, MUC4, and MUC17.
|
29778426 |
2018 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in >20% of the carcinomas.
|
29575536 |
2018 |
|
Ulcerative Colitis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This result suggests that rare alleles of the MUC3 gene may confer genetic predisposition to UC.
|
9931338 |
1999 |
|
Ulcerative Colitis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We reported a possible association of rare variable number of tandem repeat (VNTR) alleles of the "MUC3" gene with a susceptibility to UC.
|
11289722 |
2001 |
|
Endometriosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genotyping revealed that the A allele at rs10953316 in MUC17 was a protective genetic factor in endometriosis development (p = 0.008; OR = 0.53; 95% CI: 0.36-0.79).
|
26285705 |
2015 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Therefore, 13 novel loci (MOB3C‑TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, OR52E4, TCHP‑GIT2, CCDC63, 12q24.1, OAS3, PLCB2‑VPS33B, ZNF77, COL6A5, NFKBIL1‑NCR3, MUC17) were identified that confer susceptibility to early‑onset MI, hypertension, or CKD.
|
30226566 |
2018 |
|
Malignant transformation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We conclude that enhanced immunoreactivity of MUC1, MUC2 and MUC3 mucin tandem repeats occurs in adenomatous polyps and is associated with an increased risk for malignant transformation.
|
8859775 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On univariate analysis no correlation was seen with either MUC1 or MUC3 and any of the clinicopathological variables including tumour grade and stage, vascular invasion and tumour type.
|
17349047 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In colon cancers, the genetic regulation of MUC2 and MUC3 is different depending on the histological type of tumor.
|
8813081 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is a change in the pattern of the membrane associated mucins MUC1 and MUC3, part of which is in keeping with changes described in colorectal neoplasia.
|
12171961 |
2002 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Analysis of The Cancer Genome Atlas database indicated that mucin-17 (MUC17) was more highly expressed in gastric cancer (GC) specimens, with favourable prognosis for patients.
|
31262330 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Analysis of The Cancer Genome Atlas database indicated that mucin-17 (MUC17) was more highly expressed in gastric cancer (GC) specimens, with favourable prognosis for patients.
|
31262330 |
2019 |
|
Intestinal metaplasia
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Barrett's metaplasia was also associated with a specific MUC gene expression pattern, since the gastric apomucin mRNAs, MUC5AC and MUC6, were expressed in gastric metaplasia, and the intestinal apomucin mRNAs, MUC3, MUC4 and mostly MUC2, in intestinal metaplasia.
|
11093805 |
2000 |
|
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Both immunocytochemistry and in situ hybridization were used to identify cell types expressing the MUC2 and MUC3 mucins in the human small intestine, colon, and colon carcinoma.
|
8020672 |
1994 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Hyperplastic Polyp
|
0.020 |
Biomarker
|
disease |
BEFREE |
Improved diagnostic potential was revealed by multivariate logistic regression analysis where combinatorial panel of MUC5AC/MUC17 discriminated SSA/P from HP (SN/SP=85/82%).
|
27705923 |
2017 |
|
Hyperplastic Polyp
|
0.020 |
Biomarker
|
disease |
BEFREE |
Expression of MUC1, MUC2, and MUC3 core tandem repeat proteins was examined in specimens of normal mucosa (n = 20), hyperplastic polyps (n = 10), adenomatous polyps (n = 89), and invasive cancer (n = 19).
|
8859775 |
1996 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest the implication of MUC3 in renal carcinogenesis.
|
14550470 |
2003 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data demonstrate up-regulated MUC expression by ST cells and suggest a novel role of MUC3 and MUC5AC in the pathogenesis of arthritis.
|
18163520 |
2008 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specific mucin gene expression was determined using cDNA probes for 2 distinct intestinal mucins (MUC-2 and MUC-3) and one breast cancer mucin (MUC-1).
|
8443822 |
1993 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MUC2 and MUC3 staining intensity in DCIS was markedly less than that observed for MUC1.
|
11348414 |
2001 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, mice treated with MUC17-CRD1-L-CRD2 protein given per rectum demonstrated accelerated healing in acetic acid and dextran sodium sulfate induced colitis in vivo.
|
20211273 |
2010 |